Ernexa Therapeutics (ERNAW) Interest Expenses (2015 - 2023)

Ernexa Therapeutics (ERNAW) has 17 years of Interest Expenses data on file, last reported at $39000.0 in Q1 2026.

• Quarterly Interest Expenses fell 95.12% year-over-year to $39000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $39000.0 (up 100.58% YoY) and the FY2025 annual result came in at $26.1 million, changed 0.47% from the prior year.
• Interest Expenses retreated to $39000.0 in Q1 2026, from $625000.0 in the prior quarter.
• In the past five years, Interest Expenses ranged from a high of $30.7 million in Q2 2023 to a low of -$10.1 million in Q4 2024.
• A 5-year average of $2.0 million and a median of $734500.0 in 2025 frame the typical range for Interest Expenses.
• Annual changes were most pronounced in 2023 — Interest Expenses jumped 2555.67% — and 2024, when it plunged 16131.75%.
• Tracing ERNAW's Interest Expenses over 5 years: stood at -$1.2 million in 2022, then soared by 105.4% to $63000.0 in 2023, then sank by 16131.75% to -$10.1 million in 2024, then surged by 106.19% to $625000.0 in 2025, then sank by 93.76% to $39000.0 in 2026.
• The last three Interest Expenses figures came in at $39000.0 (Q1 2026), $625000.0 (Q3 2025), and $669000.0 (Q2 2025), per Business Quant data.